[Diagnostic relevancy of saralasin in renin-dependent hypertension]. 1976

A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D012504 Saralasin An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. 1-Sar-8-Ala Angiotensin II,1-Sarcosine-8-Alanine Angiotensin II,(Sar(1),Ala(8))ANGII,(Sar1,Val5,Ala8)Angiotensin II,Angiotensin II, Sar(1)-Ala(8)-,Angiotensin II, Sarcosyl(1)-Alanine(8)-,Sar-Arg-Val-Tyr-Val-His-Pro-Ala,Saralasin Acetate,Saralasin Acetate, Anhydrous,Saralasin Acetate, Hydrated,1 Sar 8 Ala Angiotensin II,1 Sarcosine 8 Alanine Angiotensin II,Angiotensin II, 1-Sar-8-Ala,Angiotensin II, 1-Sarcosine-8-Alanine,Anhydrous Saralasin Acetate,Hydrated Saralasin Acetate

Related Publications

A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
January 1979, Archives of internal medicine,
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
July 1980, Bollettino della Societa italiana di biologia sperimentale,
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
November 1978, American heart journal,
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
October 1976, The Journal of urology,
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
March 1978, Clinical science and molecular medicine,
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
February 1979, Kidney international,
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
June 1977, Mayo Clinic proceedings,
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
October 1975, Lancet (London, England),
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
April 1983, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
A Röckel, and H Wernze, and H J Spech, and E Scheitza, and H Hennemann, and A Heidland
December 1977, Nature,
Copied contents to your clipboard!